This is the same indication where the Europe’s CHMP approved Xarelto two weeks ago (#msg-80711606). JNJ is Bayer's partner on Xarelto in the US market.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”